How Many Times Can You Have TURBT For Bladder Cancer?

If you’ve been diagnosed with bladder cancer, you’re likely to come across the term TURBT – short for transurethral resection of bladder tumour.

TURBT is often the first treatment step and plays a critical role in both diagnosing and managing non-muscle-invasive bladder cancer (NMIBC). But one question many patients understandably ask is: how many times can you safely undergo TURBT?

The answer depends on various factors, including the type of bladder cancer, how often it recurs, your overall health, and the advice of your urologist.

This guide explores what TURBT involves, why repeat procedures are sometimes necessary, and what it means for your long-term treatment plan.

What is TURBT?

TURBT is a minimally invasive surgical procedure used to remove abnormal growths from the lining of the bladder. It is most commonly used for non-muscle-invasive bladder cancer, where the tumour is confined to the bladder lining and has not spread into the bladder muscle.

The procedure involves passing a thin tube with a camera and surgical loop (called a resectoscope) through the urethra and into the bladder. The tumour is then shaved away and removed, and the tissue is sent to a laboratory for examination to confirm the diagnosis and determine the grade and stage of the cancer.

Why might TURBT need to be repeated?

Bladder cancer has a high recurrence rate, especially in its non-muscle-invasive form. In fact, studies show that up to 70% of NMIBC cases may recur, even after initial successful treatment. Because of this, TURBT may need to be performed more than once. Reasons for repeat TURBT include:

Incomplete resection: Sometimes, the entire tumour cannot be fully removed during the first TURBT.
High-grade tumours: These aggressive cancers may require a second TURBT to ensure all malignant cells have been removed.
Staging confirmation: A repeat procedure may be necessary to verify whether the tumour has invaded deeper layers of the bladder wall.
Recurrence monitoring: Even after successful treatment, patients are monitored closely with regular cystoscopies. If a recurrence is found, another TURBT may be needed.

How many TURBT procedures is too many?

There is no strict upper limit on the number of TURBT procedures a person can undergo. Some patients have had multiple resections – five, ten or more – over the course of many years. The decision to perform another TURBT is based on:

The nature of the tumour (size, number, grade, and frequency of recurrence)
How well previous resections were tolerated
Presence of any complications, such as scarring or bladder capacity issues
Overall health and bladder function

For patients with frequent recurrences, your urologist may consider adjusting your management plan to include intravesical therapy (such as BCG or chemotherapy treatments directly into the bladder) or, in some cases, discuss more definitive options like bladder removal (cystectomy).

What are the risks of multiple TURBT procedures?

While TURBT is generally safe and well-tolerated, repeated surgeries do carry some risks. These can include:

Bladder wall thinning or perforation: Rare, but more likely with repeated resections.
Bleeding or infection: Common post-operative risks that increase slightly with frequent procedures.
Scar tissue formation: This can affect bladder capacity or cause urinary symptoms such as urgency or frequency.
Impact on quality of life: Repeat procedures, cystoscopies, and the anxiety of recurrence can take an emotional toll.

Your care team will carefully weigh these risks against the benefits before recommending another TURBT.

Are there alternatives to repeat TURBT?

Yes. If cancer keeps coming back or is aggressive in nature, your urologist may explore additional or alternative bladder cancer treatments, including:

Intravesical therapy: This is often given after TURBT to reduce recurrence. Options include Bacillus Calmette–Guérin (BCG) or mitomycin C.
Maintenance therapy: Ongoing instillations of BCG or chemotherapy drugs can help prevent further tumours from developing.
Enhanced cystoscopic techniques: Tools like blue light cystoscopy or narrow-band imaging can help identify tumours more clearly and reduce the chance of missing smaller growths during TURBT.
Radical treatments: In some high-risk cases where cancer keeps returning or progresses to muscle-invasive bladder cancer, cystectomy (surgical removal of the bladder) may be recommended.

How often will I need monitoring?

Surveillance is a key part of managing bladder cancer. After your initial TURBT, your urologist will recommend regular cystoscopic examinations, often every 3 to 6 months in the first few years. These check-ups help identify any signs of recurrence early and determine whether a second TURBT is necessary.

Monitoring may be less frequent if you remain cancer-free for several years, but some patients with high-risk features may require lifelong surveillance.

What should I ask my urologist?

If you’re facing multiple TURBTs or have concerns about recurrence, it’s important to have open, ongoing discussions with your urologist. Questions you may want to ask include:

Why do I need another TURBT?
What are the risks of having another resection?
Are there any alternative treatments for my type of bladder cancer?
How can I reduce my chances of recurrence?
What impact could repeat TURBTs have on my bladder function long term?

In summary

TURBT is a highly effective treatment for non-muscle-invasive bladder cancer, and it may need to be performed more than once depending on your individual case. While there is no strict limit to the number of times TURBT can be done, each procedure should be carefully considered in the context of your overall health, cancer behaviour, and treatment goals.

With regular monitoring, expert care, and a personalised treatment plan, many people go on to manage their bladder cancer successfully – even if that involves more than one TURBT along the way.

If you’re concerned about recurrent bladder cancer or facing the possibility of another TURBT, don’t hesitate to speak with your urologist. Compassionate, specialised care is available to guide you through every step of your journey.

Maneesh Ghei

Mr Maneesh Ghei MS MRCSEd MD (UCL) FRCS (Urol) is a highly experienced Consultant Urological Surgeon and founder of Urocare London, with over three decades of practice in both NHS and private settings across the capital. As Lead Cancer Clinician at Whittington Hospital, Archway, he chairs the multidisciplinary urology cancer meeting, overseeing patient care from diagnosis through to the latest minimally invasive treatments. A pioneer in complex endourology and stone disease management, Mr Ghei led the UK’s first randomised, double-blind trial of intradetrusor botulinum toxin for refractory overactive bladder. He holds an MBBS and MS in General Surgery from India, an MD from University College London, and undertook advanced fellowships in stone disease and laparoscopic surgery, culminating in his Fellowship of the Royal College of Surgeons (Urology). Committed to education and research, he supervises doctoral work in focal therapies and cryotherapy for prostate cancer and champions public awareness through annual Movember fundraising.